InsiderPulseNo transactions found.
| Metric | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Research and development | $5.6M-59.6% | $13.9M+38.5% | $10.0M+272.7% | $2.7M |
| General and administrative | $8.3M+8.8% | $7.6M+80.8% | $4.2M+205.9% | $1.4M |
| Total operating expenses | $13.9M-35.3% | $21.5M-53.6% | $46.3M+1038.8% | $4.1M |
| Loss from operations | -$13.9M+35.3% | -$21.5M+53.6% | -$46.3M-1038.8% | -$4.1M |
| Other income (expenses), net | $17K+107.7% | -$222K-208.3% | $205K+4200.0% | -$5K |
| Net loss | -$13.9M+36.1% | -$21.7M+53.3% | -$46.5M-1042.5% | -$4.1M |
| Net loss per share - basic | -$800+48.4% | -$2K | — | — |
| Net loss per share - diluted | -$800+48.4% | -$2K | — | — |
| Weighted average shares outstanding, basic | $17.38B+24.5% | $13.97B | — | — |
| Weighted average shares outstanding, diluted | $17.38B+24.5% | $13.97B | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Forte Biosciences: Targeting Celiac Disease
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences GAAP EPS of -$1.24
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update